Life, Volume 11, Issue 12
2021 December - 158 articles
Cover Story: Due to a reduced immune function in elderly patients, young patients with a robust immune system are theoretically expected to benefit more from the anti-PD1 immunotherapy approach. In contrast to this hypothesis, recent studies in patients with metastatic melanoma have demonstrated that immunotherapy, especially with anti-PD1 treatment, is less effective in patients below 65 years, on average, with significantly lower responses and reduced overall survival compared to patients above 65 years of age. Besides, data on young patients are even more sparse. Hence, in this review, we focus on age-dependent differences in the previously described resistance mechanisms to the treatment, and discuss the development of potential combination treatment strategies for enhancing the anti-tumor efficacy of anti-PD1 treatment in young melanoma patients. View this paper. - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.